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submandibular triangle (p < 0.0001). In 69% of patients (n = 11), 
the dose to the transferred submandibular gland was below the 
QUANTEC dose constraint of mean < 35 Gy. Four of the remaining 
patients had pathologic involvement of the contralateral level I 
nodes and could not have the transferred gland spared, while 
one patient had a large pT4 lip lesion and coverage of the tumour 
bed resulted in a dose of 36.0 Gy to the transferred gland. 
Conclusions: The mSGT technique significantly reduced the dose 
to the submandibular gland from a median dose very likely to 
produce xerostomia to a dose below accepted dose constraints. 
Adoption of this technique may reduce the rate of xerostomia 
and improve quality of life in patients with oral cavity cancer 
undergoing adjuvant RT. 
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Purpose: Urothelial carcinoma-associated 1 (UCA1) is a recently 
identified long non-coding RNA which plays an oncologic role in 
several cancers and enhances cellular proliferation, invasion, 
and tumour growth. It is upregulated in prostate tumours, but its 
involvement in therapy response has not been investigated. 
Methods and Materials: To simulate the clinical scenario of 
ionizing-radiation resistance (IRR), we created IRR PCa cell lines 
by treatment with mock irradiation (parental cells) or IR 
(conventional fractionation (CF): 2 Gy daily X 59 for DU145-CF-
IRR cells). We performed gene array profiling to discover 
dysregulated genes in DU145-CF-IRR cells and identified UCA1. 
We investigated the mechanism of UCA1 on aggression and 
response to radiation and chemotherapy by performing miRNA 
comparative profiling (NanoString platform), Proteome Profiler 
Array, proliferation assays, soft agar colony formation, 
clonogenic assays, invasion assay, γ-H2AX assay, cell cycle 
profiling, MTS assay and western blotting. We also studied the 
clinical significance of UCA1 expression in two cohorts of PCa 
patients; CPC-GENE (n = 210; patients with intermediate-risk 
PCa) and MSKCC (n = 131; PCa patients treated with radical 
prostatectomy).  
Results: DU145-CF-IRR cells were radioresistant and acquired an 
aggressive phenotype. We found that UCA1 expression was 
significantly higher in DU145-CF-IRR compared to parental cells 
using gene array profiling and confirmatory qRT-PCR analysis 
(170-fold). Interestingly, UCA1 siRNA-knockdown reversed the 
aggressive phenotype and significantly increased sensitivity to IR 
and docetaxel. We demonstrated that UCA1 depletion inhibited 
growth, induced cell cycle arrest at the G2/M transition and 
decreased activation of the pro-survival Akt pathway. 
Furthermore, we found that UCA1 overexpression was associated 
with a trend toward lower biochemical recurrence-free survival 
in CPC-GENE patients (HR = 1.4, p = 0.28) and its aberrant 
expression was significantly associated with decreased five-year 
disease-free survival in publically available MSKCC database 
(84.5% versus 52%; HR = 2.19, log-rank test p = 0.005).  
Conclusions: We showed for the first time that UCA1 can 
influence cancer aggression, radiation and chemotherapy 
response in PCa, which may occur through altered Akt signaling. 
Our results also suggest that UCA1 can have prognostic value in 
PCa. Future work will investigate UCA1 as a therapeutic target 
and prognostic biomarker for PCa.  
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Purpose: Pain is experienced by 50%-75% of patients with bone 
metastases, representing a major source of morbidity amongst 
cancer patients. Magnetic Resonance- Guided High Intensity 
Focused Ultrasound (MRgHIFU) is a new, non-invasive, outpatient 
treatment modality for painful bone metastases. The aim of this 
study is to analyze urinary cytokines/chemokines pattern after 
MRgHIFU for palliative treatment of painful bone metastases. 
The findings will be compared to the cytokines/chemokines 
pattern post single 8 Gy fraction radiation from our previous 
study.  
Methods and Materials: Urine samples were collected from 
patients with painful bone metastases three days before and two 
days after treatment with MRgHIFU. Each urine sample was 
tested for pro-inflammatory cytokines and anti-inflammatory 
cytokines. Patients received teaching on how to collect urine 
samples on their own. The Millipore Milliplex 42-Plex Cyto-
kine/Chemokine Kit™ was used to measure urinary levels of a 
panel of cytokines/chemokines.  
Results: Ten patients were enrolled for the study and provided 
urine samples three days before and two days after treatment 
with MRgHIFU. The following fifteen cytokines were above the 
level of detection (LOD) in at least 50% of patients at both pre-
MRgHIFU and post-MRgHIFU: EGF, Eotaxin, Fit-3 Ligand, 
Fractalkine, G-CSF, GRO, IFN-alpha2, IL-1ra, IL-8, IP-10, MCP-1, 
PDGF-AA, RANTES, sIL-2Ra, and VEGF. Nine urinary cytokines 
significantly decreased post MRgHIFU, namely, Eotaxin, GRO, IL-
8, IL-13, IP-10, MCP-1, MIP-1beta, RANTES, and sIL_2Ra. In 
addition, there were significant differences between post 
MRgHIFU and post-8 Gy fraction radiation in most urinary 
cytokines. 
Conclusions: Nine urinary cytokines significantly decreased post 
MRgHIFU which correlated with pain response in patients with 
painful bone metastases. 
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Purpose: Radiation fibrosis (RF) is a side effect of radiotherapy 
characterized by irreversible scarring of normal tissue resulting 
in functional morbidity and decreased quality of life. Adipose-
derived stromal cells (ADSCs) have been shown to regulate the 
metabolic profile of target tissue through the secretion of 
cytokines and growth factors. We hypothesize that ADSCs may be 
therapeutically effective for RF through metabolic 
reprogramming and that these ADSC-mediated metabolic 
alterations can be utilized to identify novel drugs for the 
treatment of RF.  
Method: An RF model was created by radiating the hind limb of 
C3H mice. This model showed a dose dependent leg contracture 
and histological findings of fibrosis. Primary cultured ADSCs 
derived from C3H mice were identified based on 
immunophenotyping and their differentiation potential down the 
mesenchymal lineage. 
Results: ADSC transplantation was shown to be therapeutically 
effective for RF based on an improvement in leg contracture (p 
< 0.05) and reduced collagen deposition (p < 0.01). Whole 
transcriptome over-representation and gene set enrichment 
pathway analysis revealed that lipid metabolism and glycolysis 
were two pathways strongly dysregulated in RF and were 
reversed with ADSC treatment. To identify novel drugs to be 
repurposed for the treatment of RF, ADSC-mediated 
transcriptome alterations were compared with drug-mediated 
transcriptome alterations in CMAP, a pharmacogenomics 
